会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Bearing guided labyrinth
    • 轴承引导迷宫
    • US5876126A
    • 1999-03-02
    • US928184
    • 1997-09-12
    • George MarshallRichard Harrison
    • George MarshallRichard Harrison
    • F16C33/80G11B19/20H02K5/173
    • G11B19/2009F16C33/80H02K5/173F16C2370/12
    • A motor incorporating a bearing guided labyrinth system of the present invention includes a shaft, a hub, a bearing assembly, and a bearing guided labyrinth. The bearing assembly includes an inner bearing ring and an outer bearing ring separated by a plurality of ball bearings. The inner bearing ring has an inner annular ring surface and the outer bearing ring has an outer annular ring surface. The bearing guided labyrinth has an inner prong and an outer prong. The inner prong is at least partially positionable between the inner ring surface and the shaft. The outer prong is at least partially positionable between the outer ring surface and the hub. The outer prong grips the bearing assembly and specifically the outer annular ring surface of the outer bearing ring.
    • 包括本发明的轴承导向迷宫系统的电动机包括轴,轮毂,轴承组件和轴承引导的迷宫。 轴承组件包括由多个滚珠轴承分隔的内轴承环和外轴承圈。 内轴承环具有内环形表面,外轴承环具有外环形环表面。 轴承引导迷宫有一个内部分支和一个外部分支。 内销至少部分地位于内圈表面和轴之间。 外尖头至少部分地可定位在外环表面和轮毂之间。 外部插脚夹紧轴承组件,特别是外部轴承环的外部环形表面。
    • 4. 发明申请
    • Therapeutic acridone and acridine compounds
    • 治疗吖啶酮和吖啶化合物
    • US20060111389A1
    • 2006-05-25
    • US11157977
    • 2005-06-22
    • Stephen NeidleRichard HarrisonLloyd KellandSharon GowanMartin ReadAnthony Reszka
    • Stephen NeidleRichard HarrisonLloyd KellandSharon GowanMartin ReadAnthony Reszka
    • C07D219/04A61K31/473
    • C07D219/08C07D219/06C07D219/10
    • The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones): or, (b) K is a 9-substituent. L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each independently a group of the formula —NHCO(CH2)nNR1R2, wherein: n is an integer from 1 to 5; and, R1 and R2 are independently hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(RN)Q, wherein: RN is an amino substituent and is hydrogen. C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative conditions, such as cancer.
    • 本发明涉及式(I)的吖啶酮和吖啶化合物,其中:(a)K是-O,L是-H,α是单键,β是双键,γ是单键(吖啶酮 ):或(b)K为9-取代基。 L不存在,α是双键,β是单键,γ是双键,并且其中:J 1是2-或3-取代基; J 2是6-或7-取代基; J 1和J 2各自各自独立地是式-NHCO(CH 2 CH 2)n NR n的基团, 其中:n为1至5的整数;其中n为1至5的整数; 且R 1和R 2独立地为氢,C 1-7烷基,C 3-20杂环基 或C 5-20-20芳基或R 1和R 2与它们所连接的氮原子一起形成一个 具有3至8个环原子的杂环; 并且其中当K是9-取代基时,K是式-N(R“N”)Q的基团,其中:R N是氨基取代基,并且是 氢。 C 1-7烷基,C 3-20杂环基或C 5-20-20芳基; 且Q为C 1-7烷基,C 3-20杂环基或C 5-20芳基,且为任选取代的; 和其药学上可接受的盐,酯,酰胺,溶剂合物,水合物及其保护形式。 本发明还涉及包含这种化合物的药物组合物,以及这些化合物和组合物在体外和体内都用于抑制端粒酶调节细胞增殖以及治疗增殖性疾病如癌症的用途。
    • 5. 发明申请
    • Therapeutic acridone and acridine compounds
    • 治疗吖啶酮和吖啶化合物
    • US20050070568A1
    • 2005-03-31
    • US10501474
    • 2003-01-14
    • Stephen NeidleRichard HarrisonLloyd KellandSharon GowanMartin ReadAnthony Reszka
    • Stephen NeidleRichard HarrisonLloyd KellandSharon GowanMartin ReadAnthony Reszka
    • A61K31/473A61P35/00A61P43/00C07D219/04C07D219/08C07D219/10C07D219/12
    • C07D219/08C07D219/10
    • This invention pertains to certain acridine and acridine compounds of the formula (1) which inhibit telomerase, regulate cell proliteration, etc., and/or treat cancer proliferative conditions, etc.: wherein either: (a) K is ═O, L is —H, alpha single bond beta is a double bond, gamma is a single bond (acridines); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J1 is a 2- or 3-substituent; J2 is a 6- or 7-substituent; J1 and J2 are each a group of the formula —N(RN)—W, wherein: RN is a nitrogen substituent and is hydrogen, C1-7alkyl, C3-20 heterocyclyl, or C5-20aryl, and is optionally substituted; and, W is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substitute; and wherein when K is a 9-substituent, K is a group of the formula —N(RN)-Q, wherein: RN is an amino substituent and is hydrogen, C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; and, Q is C1-7alkyl, C3-20heterocyclyl, or C5-20aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, etc., and/or in the treatment of cancer, proliferative conditions, etc.
    • 本发明涉及抑制端粒酶,调节细胞增殖等的某些式(1)的吖啶和吖啶化合物,和/或治疗癌症增殖病症等。其中:(a)K为= O,L为 -H,α单键β是双键,γ是单键(吖啶); 或(b)K是9取代基,L不存在,α是双键,β是单键,γ是双键(吖啶); 并且其中:J 1是2-或3-取代基; J 2是6-或7-取代基; J 1和J 2各自为式-N(R N)-W的基团,其中:R N为氮取代基且为氢,C 1-7烷基,C 3-20杂环基, 或C 5-20芳基,并且任选被取代; 并且W是C 1-7烷基,C 3-20杂环基或C 5-20芳基,并且任选被取代; 并且其中当K是9-取代基时,K是式-N(R N)-Q的基团,其中:R N是氨基取代基并且是氢,C 1-7烷基,C 3-20杂环基, 或C5-20芳基; 且Q为C 1-7烷基,C 3-20杂环基或C 5-20芳基,并且任选被取代; 和其药学上可接受的盐,酯,酰胺,溶剂合物,水合物及其保护形式。 本发明还涉及包含这种化合物的药物组合物,以及这些化合物和组合物在体外和体内的用途,以抑制端粒酶,调节细胞增殖等,和/或治疗癌症,增殖性 条件等
    • 10. 发明申请
    • Polymerisation of ethylenically unsaturated monomers
    • 烯属不饱和单体的聚合
    • US20070037938A1
    • 2007-02-15
    • US10549856
    • 2004-03-24
    • Richard HarrisonBruce GilbertAndrew ParsonsDerek Irvine
    • Richard HarrisonBruce GilbertAndrew ParsonsDerek Irvine
    • C08F2/00B01J31/00
    • C08F4/50
    • Ethylenically unsaturated, particularly acrylic, monomers are polymerised using a catalyst system including a manganese carbonyl initiator, an organic halogen reactive substrate and an allylic halide chain termination agent. Desirably the manganese carbonyl initiator is a dimanganese compound, particularly dimanganese decacarbonyl (Mn2(CO)10). The catalysis mechanism appears to involve initiator homolysis, abstraction of halogen from the reactive substrate forming an organic free radical which acts as a chain initiator for polymerisation and eventual reaction of the propagating chain radical with the chain terminating agent. The speed or extent of reaction may be modified by the inclusion of Lewis acids in the reaction mixture. The resulting polymers are telechelic and may have different end groups. The polymers can be reacted further to functionalise them and/or to form block copolymers.
    • 使用包括羰基羰基引发剂,有机卤素反应性底物和烯丙基卤化物链终止剂的催化剂体系来聚合乙烯基不饱和的,特别是丙烯酸的单体。 期望地,羰基羰基引发剂是二甘氨酸化合物,特别是二甘氨酸的十羧基(Mn 2 N(CO)10))。 催化机理似乎涉及引发剂均聚,从反应性底物中提取卤素,形成有机自由基,其起到用于聚合的链引发剂和增链链基团与链终止剂的最终反应。 可以通过在反应混合物中加入路易斯酸来改变反应的速度或程度。 所得聚合物是遥爪的并且可以具有不同的端基。 聚合物可进一步反应以使其功能化和/或形成嵌段共聚物。